In 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of Nasdaq First North for the accounting of Kancera AB....
Read MoreKancera reports that a second efficacy study of the drug candidate KAN0439834 (small molecule inhibitor of ROR1) has been completed in an animal model of an advanced stage of chronic lymphocytic leukemia. The results show that KAN0439834 reduces the...
Read MoreKancera reports that an investigation of the mechanism of action of the company's patent-pending HDAC6 inhibitors has demonstrated a unique profile that could strengthen the competitiveness of the project.
Read MoreJanuary 1 - September 30, 2014. All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. In connection with this Kancera...
Read MoreKancera reports the results of an analysis of the preclinical efficacy study that was completed during the third quarter as reported in a press release on October 3, 2014. The results confirm that the number of cancer cells in...
Read MoreKancera reports that an initial efficacy study of KAN0439834 (a small molecule inhibitor of ROR1) has been completed in an animal model of chronic lymphocytic leukemia. Preliminary results show that KAN0439834 reduces the number of ROR-expressing leukemia cells after...
Read MoreIn connection with presentations for pharmaceutical companies and universities during the "U.S. Cancer Immunotherapy Partnering Mission" (CIPM), 15 -19 September 2014, Kancera communicates new information regarding the company's ROR1-directed small molecules and vaccine candidates. This information concerns the efficacy...
Read MoreJanuary 1 - June 30, 2014 All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. In connection with this Kancera...
Read MoreAll figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read MoreKancera reports that the company has registered a patent application (EP14167988.6) for new compounds against cancer that selectively inhibit the enzyme HDAC6. The new patent application is based on the ability of HDAC6 inhibitors to influence mechanisms both inside...
Read More